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Whereas neuroblastoma (NB) with MYCN amplification presents a poor prognosis, no single marker allows to reliably predict
outcome in tumours without MYCN amplification. We report here an extensive analysis of 147 NB samples at diagnosis, without
MYCN amplification, by chromosomal comparative genomic hybridisation (CGH), providing a comprehensive overview of their
genomic imbalances. Comparative genomic hybridisation profiles showed gains or losses of entire chromosomes (type 1) in 71 cases,
whereas partial chromosome gains or losses (type 2), including gain involving 17q were observed in 68 cases. Atypical profiles were
present in eight cases. A type 1 profile was observed more frequently in localised disease (Po0.0001), and in patients of less than 12
months at diagnosis (Po0.0001). A type 2 genomic profile was associated with a higher risk of relapse in the overall population (log-
rank test; Po0.0001), but also in the subgroup of patients with localised disease (log-rank test, P¼0.007). In multivariate analysis, the
genomic profile was the strongest independent prognostic factor. In conclusion, the genomic profile is of prognostic impact in patients
without MYCN amplification, making it a help in the management of low-stage NB. Further studies using higher-resolution CGH are
needed to better characterise atypical genomic alterations.
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Neuroblastoma (NB), the most frequent extracranial solid tumour
of childhood, is characterised by a wide variability of its clinical
course, with a possibility of cellular maturation or spontaneous
tumour regression on the one hand, or aggressive clinical
behaviour with rapid progression despite intensive therapeutic
approaches on the other hand.
Clinical markers, such as stage and age at diagnosis, are
insufficient to precisely predict outcome in all patients. This had
led to the search for additional markers that might enable a more
robust prognostic classification of NB (Brodeur et al, 1997, 2003;
Maris and Matthay 1999; Maris, 2005). Several recurrent genetic
alterations have been identified in NB. Amplification of the MYCN
oncogene is observed in approximately 20% of cases and is clearly
associated with a poor outcome (Seeger et al, 1985). Variations of
the ploidy have also been described in NB, with near-triploidy
associated with an excellent outcome, and diploidy/tetraploidy
correlating with a poorer outcome (Look et al, 1991). Finally, a
number of segmental chromosome alterations have been reported.
Deletions of chromosome 1p, observed in approximately 25% of
cases, and more recently deletions of 3p and 11q, thought to
harbour yet unidentified tumour suppressor genes, have also been
associated with a poor outcome (Caron et al, 1996; Schleiermacher
et al, 1996; Luttikhuis et al, 2001; Attiyeh et al, 2005). Other
recurrent chromosome losses involve chromosomes 4p, 9p, or 14q.
Gain of chromosome 17q, harbouring hypothetical oncogenes,
which might play a role in the oncogenesis of NB, represents the
most frequent genetic abnormality in NB, and is thought to be a
powerful independent predictor of poor outcome (Plantaz et al,
1997; Bown 2001; Brinkschmidt et al, 2001; Lastowska et al, 2001).
Until now, these various genetic markers are analysed separately
by conventional karyotyping, 24-colour karyotyping, FISH and/or
LOH studies (Ambros et al, 2003), making these analyses time
consuming and rendering their interpretation difficult as not all
markers could be studied at one time. During the last decade,
pangenomic techniques such as comparative genomic hybridisa-
tion (CGH), which enable the analysis of the entire tumour genome
in one step, identifying DNA copy number gains and losses across
the whole karyotype, have been developed (Kallioniemi et al,
1992). The CGH technique constitutes a highly efficient and
discriminative approach for the analysis of tumours characterised
by quantitative genetic changes, which is the case in NB.
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identification of distinct genetic subtypes with specific prognostic
characteristics (Brinkschmidt et al, 1997, 1998; Vandesompele
et al, 1998, 2001; Lastowska et al, 2001; Plantaz et al, 2001). A
genomic profile characterised by whole chromosome gains or
losses, defining type 1 tumours (Lastowska et al, 2001), is observed
more frequently in localised tumours and in children less than 1
year of age, with a good prognosis. On the other hand, unbalanced
chromosome translocations leading to segmental chromosome
gains or losses, including in particular chromosome 17q gain
associated with either loss of 11q and 3p, or 1p (type 2 tumours),
are observed more frequently in advanced stages of disease or
older children, with an intermediate prognosis. Finally, tumours
presenting MYCN amplification in addition to segmental chromo-
some alterations (type 3 tumours) show highly aggressive clinical
behaviour and a poor outcome. It has been suggested that these
subtypes represent distinct pathologies as transitions from one
type to another appear to be rare.
A more recent study based on the pooled CGH data of 231
samples from several institutions has confirmed this classification
(Vandesompele et al, 2005). Variations in the copy number of
whole chromosomes was more frequently observed in localised
disease, of favourable histology, and in infants, with recognition of
a survivor signature conferring 100% 5-year survival in stage 1, 2
or 4s tumours presenting with whole chromosome 17 gain,
whereas structural aberration patterns were a significant predictor
of poorer outcome.
The interpretation of previous results may be hampered by the
heterogeneity of techniques and by the inclusion of MYCN
amplified tumours. The prognostic value of MYCN amplification
is so strong that, in a clinical setting, the need for reliable genomic
typing mainly concerns MYCN non-amplified tumours. To date,
no study has focused specifically on the analysis by CGH of this
subset of NB, so we report here the results of an extensive analysis
by chromosomal CGH of 147 NB samples without MYCN
amplification, in order to assess the clinical usefulness of this
pangenomic technique for the genomic typing of these tumours.
MATERIALS AND METHODS
Patients
Patients with a histologically confirmed diagnosis of NB were
included in this study, if frozen tumour material obtained at the
time of diagnosis was available for DNA extraction. Only cases
without MYCN amplification were included. Patients were treated
in centres of the Socie ´te ´ Franc¸aise des Cancers de l’Enfant (SFCE)
between 1990 and 2003, according to the ongoing national or
international treatment protocols: for infants less than 1 year at
diagnosis, NBL90 or INES99; for patients with localised resectable
disease, LNESG1; for patients with localised unresectable disease,
NB94 or NB02; for patients with metastatic disease, NB87ter or
HR-NBL-01. Inclusion in the clinical trials was performed
according to the relevant French law, following informed consent.
A total of 147 patients were included. The clinical characteristics
of the patients corresponded to those described in NB in general
(Brodeur, 2003). The median age of patients at diagnosis was 12
months (range 0–175 months). Median follow-up was 57.3 months
(range 17–194 months). Tumours were stages 1 or 2 in 67 cases,
stage 3 in 10 cases, stage 4 in 60 cases and stage 4S in 10 cases
(Table 1a and b). There have been 50 relapses or disease
progressions, of which eight occurred only at local sites, whereas
38 involved metastatic sites; the site of relapse was unknown in
four cases. Of the 147 patients, 25 have died of disease, three have
died of treatment toxicity and one of other cause, whereas the
other 118 are alive (seven with progressive disease, two with stable
disease, eight in partial remission, 101 in complete remission).
Tumour samples
Tumour samples were obtained at the time of diagnosis by needle-
core or surgical biopsy, primary surgery or fine-needle aspiration.
For biopsies and surgical fragments, the tumour cell content was
systematically checked on haematoxylin/eosin-stained frozen
section of the sample submitted to DNA extraction. Fine-needle
aspirates were checked by the cytologist on May–Gru ¨nwald–
Giemsa-stained spreads. Only cases with more than 60% tumour
cells were included (Ambros et al, 2003). The MYCN status was
assessed by FISH using a MYCN probe (Zymed Laboratories, San
Francisco, CA, USA) on frozen sections for tumour fragments,
and on cytogenetic preparations for fine-needle aspirates. Tumours
showing an average number of signals per nucleus 410 were
considered as having an amplification, and were excluded from the
study. Rare cases showing a borderline count of signals were
checked with a centromeric probe of chromosome 2, and those
showing a ratio MYCN/centromere signal 44 were considered as
amplified and excluded. The whole tissue sections or cell spreads
were thoroughly examined, in order to detect eventual hetero-
geneous amplifications (Ambros et al, 2001), but none was found.
CGH analysis
Comparative genomic hybridisation was performed in one
laboratory, as previously described (Kallioniemi et al, 1992).
Briefly, tumour DNAs were labelled using a SpectrumGreen-dUTP
(Vysis, Downers Grove, IL, USA) and a dedicated nick-translation
kit (Vysis). SpectrumRed normal male DNA (Vysis) was used as
reference. The hybridisation mixture was composed of 400ng of
Table 1a Genetic markers according to genomic profiles
a
CGH type
Genetic marker 1 (n¼71) 2a (n¼53) 2b (n¼15) Atypical (n¼8)
Chr 1p No deletion 71 53 0 8
Deletion 0 0 15 0
Chr 2p No gain 71 39 7 8
Gain 0 14 8 0
Chr 3p No deletion 71 34 9 8
Deletion 0 19 6 0
Chr 11q No deletion 71 10 6 7
Deletion 0 43 9 1
Chr 17q No gain 71 1 3 6
Gain 0 52 12 2
Abbreviation: CGH, comparative genomic hybridisation.
aTaking into account only
partial chromosome imbalances.
Table 1b Clinical characteristics according to genomic profiles
CGH type
Clinical characteristics 1 2a 2b Atypical P
a(w
2-test)
Stage (INSS) 1 or 2 50 11 3 3
37 2 0 1
4 5 40 12 3
4s 9 0 0 1 o0.0001
Age (months) p12 54 9 7 4
412 17 44 8 4 o0.0001
Localisation Abdominal 40 43 12 5
Extra-abdominal 19 6 3 3
Not known 12 4 0 0 o0.05
Abbreviation: CGH, comparative genomic hybridisation.
aAtypical cases excluded.
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(Invitrogen, Cergy-Pontoise, France) in 15ml hybridisation buffer
(formamide 50%/NaH2PO4 40mM/SDS 0.1%/dextran sulphate
10%/2X SSC). Comparative genomic hybridisation images of a
minimum of 10 metaphases were captured with an epifluorescence
Leica DMRB microscope fitted with a Photometrix CoolSnap fx
digital camera, and analysed with Quips software (Vysis). For
scoring chromosome imbalances, gains corresponded to green/red
fluorescence ratios 41.2, and losses to ratios o0.8. Special
attention was paid to the pattern of chromosome 1p imbalances,
because of possible difficulties of interpretation described for this
region (Kallioniemi et al, 1994). A loss was retained when the shift
of the profile was clear and the green/red fluorescence ratio similar
to that of other lost genomic regions, or, in case of ambiguous
imbalance, when it was confirmed by FISH or array-CGH results.
On the whole (94% of the cases), profiles of individual tumours
could be classified into three genomic types, according to a typing
adapted from Lastowska et al (2001): type 1, showing gains and
losses of entire chromosomes; types 2, showing partial chromo-
some gains and losses of the chromosome regions known to be
recurrently involved in NB (i.e., 1p, 2p, 3p, 11q and 17q), without
(type 2a) or with (type 2b) 1p deletion, among other imbalances.
Statistical analysis
Correlation between clinical and molecular data was assessed by
using the w
2-test. Event-free survival (EFS) and overall survival
(OS), indicated with the standard deviation, were estimated with
the Kaplan–Meier method and compared by the log-rank test. A
P-value of less than 0.05 was considered significant. Event-free
survival was calculated from diagnosis until the date of last follow-
up or event (tumour progression or relapse). Overall survival was
calculated from diagnosis to the last follow-up or disease-related
death. Multivariate analysis was conducted on EFS, using a Cox
regression model, with a backward procedure.
RESULTS
CGH
Genomic typing using chromosomal CGH enabled the identifica-
tion of distinct profiles. Comparative genomic hybridisation
profiles showed only gains or losses of entire chromosomes in
71 cases (48% of all cases) (genomic type 1; Figure 1). Partial
chromosome gains or losses, including gain of the chromosome
17q region, without or with deletion of chromosome 1p (type 2a
or type 2b), were observed in 53 (36%) and 15 (10%) cases,
respectively (Figure 2A and B; Table 1a). Among four cases
showing a questionable 1p deletion, one was confirmed by the
FISH result, the three other did not show any deletion by FISH
and/or array-CGH, and were classified as type 2a. Eight additional
tumours could not be classified into these genomic types, and were
considered as having an atypical profile.
Genomic type 1 In these tumours, the most frequent imbalance
was whole chromosome 17 gain, observed in 77% of the cases,
followed by  14, þ7,  4,  3,  11,  21, þ2, þ13, þ18,  19,
þ5, þ6,  16, each present in more than 20% of cases.
Genomic types 2 Types 2a and 2b represented 78 and 22% of all
genomic type 2 cases, respectively. All of these tumours showed
17q gain, except one type 2a and three 2b tumours, having a gain
of an entire chromosome 17, but associated with typical segmental
imbalances of other chromosomes. Main segmental imbalances
other than 17q gain were 11q and 3p deletions (78 and 37% of type
2 cases, respectively), 2p gain (32%) and 4p deletion (22%).
Among the 53 type 2a tumours, 17 cases had deletions of both 3p
and 11q, two had deletion of 3p without deletion of 11q, 26 had
deletion of 11q without deletion of 3p and eight did not have either
of these aberrations. Among the 15 type 2b cases, in addition to
chromosome 1p deletion, six also had deletion of both 3p and 11q,
whereas three others had deletion of 11q without deletion of 3p.
Some of these cases also showed few whole chromosome
imbalances, involving mainly gains of chromosomes 7, 12, 13
and 18, in addition to the segmental changes.
Atypical genomic types For four tumours, no genomic alterations
could be identified, despite sufficient tumour cell content of the
sample and confirmation of the histological diagnosis. In three
other cases, segmental alterations not typically observed in NB
were observed (case 93:  19p,  22; case 94:  11q14q25,
 14q21q32 without chromosome 17q gain; case 142:
þ17p11.2q25 without segmental loss). For a last case (case 41),
two samples from the same tumour had been received from the
pathologist and were separately analysed. A 1p loss was present in
addition to other segmental abnormalities in one of the samples
only, so the tumour could not be assigned to 2a or 2b type, and was
classified into the atypical group.
Clinical characteristics according to the genetic subtypes
The clinical characteristics in the different genetic subgroups are
presented in Table 1a and b. The distribution of frequency of the
different variables was not random (Table 1b). A genomic type 1
12 3 4 56
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Figure 1 Diagram showing gains and losses detected by chromosomal
CGH in tumours with a type 1 genomic profile, characterised by numerical
chromosome alterations. Losses are indicated by a bar on the left and gains
by a bar on the right of each chromosome ideogram. Each bar represents
an alteration observed in one tumour.
Chromosomal CGH in neuroblastoma
G Schleiermacher et al
240
British Journal of Cancer (2007) 97(2), 238–246 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sprofile was observed more frequently in localised disease (stages
1–3; Po 0.0001), and in patients of less than 12 months at
diagnosis (Po 0.0001), whereas type 2a/2b profiles occurred more
frequently in stage 4 disease, in patients older than 12 months, and
in tumours located in the abdomen.
Univariate survival analysis
The eight tumours with atypical profiles were excluded from the
survival analysis. Among the 139 remaining patients, EFS at 4 years
was 65.974.2 % and 4-year OS was 87.173.0% (Table 2; Figure 3A
and B). As expected, patients with stage 4 disease and those aged
over 12 months at diagnosis had a poorer EFS and OS (Po 0.0001;
Figure 3C and D). Patients with an abdominal primary had a
poorer OS (Po 0.04).
Single genetic markers, including chromosome 3p and 11q
deletions and chromosome 2p and 17q gains, were all associated
with a significantly poorer EFS and OS (Figure 4A and B).
Chromosome 1p deletion was not associated with statistically
significant poorer EFS and OS.
In addition to the single genetic markers, the genomic type also
proved to be of prognostic significance. Indeed, patients with a
type 1 genomic profile had a significantly better EFS and OS
(Figure 4C). In the entire population, only one patient with a type 1
CGH profile has died. This patient, aged 2 years, had metastatic
disease at diagnosis and subsequent metastatic relapse.
Comparative genomic hybridisation profiles of type 2a and 2b
were associated with a higher risk of relapse or progression in the
overall population, and with a poorer outcome (log-rank test, Po
0.0001). No difference in EFS or OS between CGH types 2a and 2b
could be observed (log-rank test; P¼0.2 and P¼0.8, respectively).
Among patients with type 2a or 2b tumours, those with 11q
deletion did not have a higher risk of relapse than those without
chromosome 11q deletion (log-rank test; P¼0.14), but did have a
poorer overall survival (log-rank test; P¼0.03).
In NB, local recurrences can often be successfully treated,
whereas metastatic relapse still represents a major challenge. We
therefore analysed the impact of the genomic profile on metastatic
free survival. Type 2a and 2b genomic profiles were associated with
a significantly poorer metastatic free survival in the overall
population (Figure 4D).
Survival analysis in patients with localised disease
Whereas in 66 patients with metastatic disease, 33 of 36 relapses
occurred at a metastatic level, among the 73 patients with localised
disease, over half of the relapses consisted of purely local relapses
(8/13, 61%; Table 3). Only four patients with initially localised
disease had metastatic relapse, and, of these, two had a type 2a or
2b genomic profile. The tumours of the other two patients with a
type 1 genomic profile will certainly merit further investigation.
Among patients with localised disease, those with a type 2a or type
1 2 3 4 5
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X
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6 7 8 91 0
11 12 13 14 15
17
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AB
Figure 2 Diagram showing gains and losses detected by chromosomal CGH in tumours with a type 2 genomic profile, characterised by segmental
chromosome alterations. Losses are indicated by a bar on the left and gains by a bar on the right of each chromosome ideogram. Each bar represents an
alteration observed in one tumour. (A) Segmental alterations observed in tumours without chromosome 1p deletions (type 2a). (B) Segmental alterations
observed in tumours with chromosome 1p deletions (type 2b).
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to those with a type 1 profile (log-rank test; P¼0.005).
Regression model
In a final step, multivariate analysis using a regression model on
EFS, progressively removing variables in case of P40.05, was
performed, according to a Cox model. The variables age, stage,
status of 1p, 2p, 3p, 11q and 17q, as well as the CGH profile, were
used in the model. In this model, the CGH profile (type 2a or 2b vs
type 1) was the strongest independent prognostic factor (RR 4.4;
P¼0.0004; Table 4).
DISCUSSION
Neuroblastic tumours without MYCN amplification are charac-
terised by combinations of non-random genomic alterations
consisting of numerical chromosome variations on the one hand,
and segmental chromosome imbalances related to unbalanced
translocations on the other hand. Chromosome CGH, and more
Table 2 EFS and OS according to clinical and genetic markers
Marker 4-year EFS (%)7s.e. P (log rank) 4-year OS (%)7s.e. P (log rank)
Entire population 65.974.2 87.173.0
Age at diagnosis p12 months 8774.1 100
412 months 43.476.6 o0.0001 73.375.8 o0.0001
Stage 1,2,3 or 4s 84.674.3 100
4 45.876.5 o0.0001 6976.5 o0.0001
Tumour localisation Extra-abdominal 78.677.8 96.373.6
Abdominal 61.175.3 ¼0.08 83.574.1 o0.04
Chromosome 1p No deletion 67.074.4 87.973.2
Deletion 59.3712.9 NS 80710.3 NS
Chromosome 2p No gain 72.174.3 90.372.9
Gain 33.1710.9 ¼0.0001 68.6710.7 ¼0.0002
Chromosome 3p No deletion 72.574.4 92.172.7
Deletion 36.5710 o0.0001 64710.4 ¼0.0002
Chromosome 11q No deletion 84.274.1 98.871.2
Deletion 36.676.9 o0.0001 68.376.8 o0.0001
Chromosome 17q No gain 8574.2 97.272
Gain 44.776.5 o0.0001 75.975.7 o0.0001
CGH type Type 1 88.673.8 98.671.4
Type 2a or 2b 43.576.3 o0.0001 75.875.5 o0.0001
Abbreviations: CGH, comparative genomic hybridisation; EFS, event-free survival; OS, overall survival.
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Figure 3 Survival curves of 139 neuroblastoma patients. (A) Event-free survival of all patients. (B) Overall survival of all patients. (C) Event-free survival
according to stage at diagnosis. (D) Event-free survival according to age at diagnosis.
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imbalances in a single experiment (Kallioniemi et al, 1992). To
date, several series of CGH analyses of non-selected NBs including
MYCN amplified cases have been published, mostly consisting of
data from several centres (Brinkschmidt et al, 1997; Lastowska
et al, 2001; Vandesompele et al, 2005). These previous analyses
have shown that, using CGH, tumours could be classified into
genomic groups associated with distinct clinical characteristics.
We have now performed chromosomal CGH of NB samples
obtained from centres of the SFCE in a single laboratory, in order
to determine if pangenomic genotyping could be useful for the
management of MYCN non-amplified tumours in a clinical setting.
Our study clearly shows that pangenomic analysis enables the
determination of distinct genomic profiles. To date, no common
international consensus nomenclature exists for the description of
the different genomic types, and we have adapted the previously
published categories (Lastowska et al, 2001). Among type 1
profiles, alterations, by order of frequency, were gains of
chromosomes 17, 7, 2, 13 and 18, and losses of chromosomes 14,
4, 3, 11, 19 and 21, consistent with previous reports. Among
tumours with partial chromosome imbalances, thought to arise
from unbalanced translocations, gains of chromosome 17q were
observed most frequently, as reported previously. Other recurrent
segmental imbalances were deletions of 11q, 3p or 4p and gain of
2p. Taking into account the clinical importance given until now to
1p status, we have, as a first approach, divided type 2 tumours into
subtype 2a (normal chromosome 1) and subtype 2b (presence of
1p deletion). The majority of all samples could be classified
according to these criteria (139/147). Only eight cases could not be
classified; four did not have any genomic imbalance detected by
CGH, despite an adequate tumour cell content of the sample. This
may possibly be explained by the presence of very small segmental
alterations below the resolution of CGH, or by a purely triploid
chromosome number. Finally, four other tumours showed
segmental chromosome gains or losses in an atypical pattern.
The resolution of chromosomal CGH of one sub-band, or
approximately 10Mb, does not allow the analysis of chromosome
breakpoints in detail. Whereas breakpoints are widely dispersed
along chromosome arms 1p, 2p, 3p and 17q, they lie closer
together on chromosome 11q, at 11q23, in accordance with
published data (Schleiermacher et al, 2004; Stallings et al, 2004;
White et al, 2005; Spitz et al, 2006). Further studies using FISH or
high-resolution CGH will be needed to map the breakpoints
precisely.
A large number of studies have shown an association between
genetic markers and clinical characteristics. Indeed, it has been
shown that the presence of structural abnormalities due to
unbalanced chromosome translocations is clearly associated with
advanced stages of disease (Lastowska et al, 2001; Bilke et al, 2005;
Vandesompele et al, 2005). These unbalanced translocations most
frequently involve chromosome 17q as the donor and chromo-
somes 1p, 3p or 11q, amongst others, as the recipient chromosome,
leading to genomic imbalance. The most frequent genomic
imbalance observed in high risk NB is chromosome 17q gain
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Figure 4 Survival curves according to genetic markers. (A) Event-free survival according to chromosome 11q status. (B) Event-free survival according to
chromosome 17q status. (C) Event-free survival according to the genomic profile, type 1 referring to numerical alterations, and type 2a and 2b referring to
structural chromosome alterations without or with chromosome 1p loss. (D) Metastasis-free survival according to the genomic profile.
Table 3 Frequency and site of relapse according to the CGH profile
Type of relapse
Stage of
disease
CGH type 1
(n¼71)
CGH type 2a
(n¼53)
CGH type 2b
(n¼15)
Localised
disease
Local: 3 Local: 3 Local: 2
(stage 1, 2 or 3) Metastatic: 2 Metastatic: 2
(n¼73) Unknown: 1
Metastatic
disease
Local: 0 Local: 0 Local: 0
(stage 4 or 4s) Metastatic: 2 Metastatic: 26 Metastatic: 5
(n¼66) Unknown: 3
Abbreviation: CGH, comparative genomic hybridisation.
Chromosomal CGH in neuroblastoma
G Schleiermacher et al
243
British Journal of Cancer (2007) 97(2), 238–246 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s(Lastowska et al, 1997; Bown et al, 1999), with other copy number
changes involving chromosome 11q loss, often associated with
chromosome 3p loss, in the absence of 1p loss (Breen et al, 2000;
Plantaz et al, 2001). In this study, a clear association between
the presence of genomic imbalances, as in type 2a and type 2b
tumours, and advanced stage of disease is also observed. An
association between deletion of chromosome 11q and 3p is also
observed. However, the analysis of type 2b profiles shows that 1p
and 11q deletions are not exclusive. On the other hand, previous
studies have shown that localised tumours or those occurring in
infants o1 year of age have numerical rather than structural
abnormalities (Bilke et al, 2005; Vandesompele et al, 2005). In our
series, a type 1 genomic profile is also associated with an age o1
year at diagnosis and with localised disease. It has also been shown
that in stage 4s tumours, structural abnormalities are observed in
cases with aggressive clinical behaviour, whereas spontaneously
regressing tumours more frequently have numerical aberrations
(Brinkschmidt et al, 1998).
In this study, established clinical factors were of prognostic
significance, such as tumour stage and age at diagnosis. We used
an age cut-off of 12 months, rather than the age of 18 months
suggested recently (London et al, 2005), as the treatment protocols
according to which patients were treated were based on the 12-
month cut-off. Furthermore, nearly all genetic markers have been
shown to be of prognostic significance in univariate analysis.
Chromosome 17q gain, the most frequent genetic alteration in NB,
is associated with a poor outcome (Abel et al, 1999; Bown et al,
1999; Brinkschmidt et al, 2001). More recently, a study looking at
1p and 11q status by determining LOH has shown a strong
prognostic impact of imbalanced 11q loss (Attiyeh et al, 2005).
Chromosome 1p and 3p loss, as well as 2p gain, have also been
associated with a higher risk of relapse (Caron et al, 1996; Ejeskar
et al, 1998; Maris and Matthay, 1999; Spitz et al, 2003, 2006). In this
study, consistent with these previous observations, single genetic
markers, including loss of 3p and 11q and gain of 2p and 17q, are
all strong predictors of poor outcome. Deletion of 1p is not
associated here with a poor outcome in univariate analysis in the
overall population. However, patients with a 1p deletion did have
higher risk of relapse when compared to only those with a type 1
genomic profile. These results indicate that 1p deletion is a marker,
which identifies only a small subgroup of patients at risk in the
global population.
To date, few studies have focused on the prognostic impact of
these various genetic markers in a multivariate setting, especially
in MYCN non amplified tumours. Taking into account the well-
known prognostic value of MYCN amplification, the only genetic
marker retained in clinical protocols in Europe at present,
pertinent genomic stratification is especially needed in MYCN
non amplified low stage and infant tumours. Our study now
suggests that the presence of any of the segmental alterations
typically observed in NB, grouped together in the type 2 genomic
profile, is strongly associated with a higher risk of relapse, a higher
risk of metastatic relapse, as well as a poorer outcome in the
overall population. Furthermore, a genomic type 2 profile is
associated with a higher risk of relapse, and a higher risk of
metastatic relapse among the patients with localised disease. The
findings of this study are in accordance with a recent report
indicating that structural abnormalities of chromosomes 1p, 3p,
11q and 17q are observed more frequently in tumours with
recurrence (Spitz et al, 2006). In this study, among patients with
localised disease, only two with a type 1 genomic profile had
metastatic relapse. These tumours certainly merit further analysis
using high resolution CGH in order to search for small segmental
alterations not detected by chromosomal CGH. Our data indicate
that maximal prognostic information can be obtained when
looking at the entire genomic profile. Furthermore, detailed
analysis using higher-resolution array-CGH of a more extensive
series of samples is needed to answer the question if the atypical
profiles harbouring segmental alterations not typically observed
in NB may also be associated with a higher risk. More detailed
pangenomic analyses with higher resolution are required to
perform a better genomic classification of tumours, to advance
in the classification of atypical profiles, and to determine a
common nomenclature.
Genomic profiles provide a comprehensive overview of genomic
changes in NB and are of prognostic impact in patients without
MYCN amplification, making them a help in the management
specifically of low stage tumours. Indeed, treatment desescalation
could possibly be proposed in future clinical trials for some patient
subgroups, as for instance for infants with asymptomatic, non-
resectable low-stage tumours. In case of a type 1 genomic profile,
the feasibility of an observational attitude could be investigated,
whereas patients with type 2 tumours could be excluded from
treatment desescalation. On the other hand, more intensive
therapy could be discussed for other patient subgroups, such as
older patients with a localised but unresectable tumour, with a type
2 profile.
In conclusion, the genomic profile is thought to be representa-
tive of an underlying genomic abnormality. In tumours with
numerical aberrations, an abnormality in the mitotic segregation
of the chromosomes is thought to exist. On the other hand, the
structural chromosome alterations in high- and intermediate-risk
tumours are most frequently due to unbalanced chromosome
translocations, which in turn are thought to arise from DNA
double-strand breaks repaired erroneously. A DNA maintenance
or repair pathway is most likely impaired. We have recently
suggested that the DNA repair mechanism leading to the DNA
double strand-breaks is most likely break-induced replication
(Janoueix-Lerosey et al, 2005; Schleiermacher et al, 2005). Thus,
the single genetic alterations could be considered as surrogate
markers for an underlying abnormality, which will confer
additional selective advantage to tumour cells. This study suggests
that a pangenomic analysis should be performed for all NB at
diagnosis for a better understanding of the oncogenesis of NB and
for better therapeutic stratification.
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